Given that these activities activate the brain, it may not be surprising that CivicScience Wellbeing Index scores rebounded among GLP-1 users in June, thanks to a decline in reported strong feelings of sadness and fear
Responses were sorted based on inquiry type, and were then analyzed to determine the most important findings of the study.
Understanding obesity as a chronic, relapsing illness GLP-1s fold into the treatment conversation for obesity because the cultural discourse around obesity is changing
In a Ro-sponsored Instagram post, Williams said she lost 31 pounds while taking Zepbound
Cardiovascular outcomes trials have demonstrated reduced rates of major adverse cardiovascular events in high-risk patients treated with liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial)
Phase 2 Trial Results (NEJM 2023) The landmark Phase 2 trial enrolled 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27) but without diabetes